Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Apollomics Inc. Warrant (APLMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: APLMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.66M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 |
52 Weeks Range 0.03 - 0.03 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20542439 | Price to Sales(TTM) - |
Enterprise Value 20542439 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Apollomics Inc. Warrant
Company Overview
History and Background
Apollomics Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of immuno-oncology therapies and combination therapies to treat cancer. The warrant likely derives from a SPAC merger or other financial instrument related to the company. Given that Apollomics is no longer actively trading, the warrant's value is intrinsically linked to any residual assets or legal claims.
Core Business Areas
- Drug Development: Focused on research, development, and clinical trials of cancer therapies, especially immuno-oncology approaches.
Leadership and Structure
Specific leadership details are difficult to ascertain as the company is no longer actively operating.
Top Products and Market Share
Key Offerings
- APL-101: A targeted therapy candidate, but not actively marketed. There is no market share data currently available due to Apollomics not being actively traded.
- APL-106: Another drug candidate in development, focused on cancer treatment. There is no market share data currently available due to Apollomics not being actively traded.
Market Dynamics
Industry Overview
The biopharmaceutical industry, especially immuno-oncology, is highly competitive with numerous companies developing and marketing cancer therapies.
Positioning
Apollomics previously aimed to position itself within the immuno-oncology space; however, its current status limits its market presence.
Total Addressable Market (TAM)
The global oncology market is vast, estimated to be in the hundreds of billions of dollars. Apollomics was positioning itself to capture a portion of this market, but is no longer an active participant.
Upturn SWOT Analysis
Strengths
Weaknesses
- Lack of Current Operations
- No Active Revenue Generation
- Uncertainty regarding warrant value
- Dilution
Opportunities
- Potential for Acquisition of Remaining Assets
- Legal Settlements Yielding Value
Threats
- Complete Loss of Value
- Legal Challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
N/A
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the company's focus on R&D and clinical trials.
Future Projections: No viable projections given the company's current status.
Recent Initiatives: No recent initiatives.
Summary
Apollomics Inc. warrant represents a highly speculative investment. The company is no longer actively operating, thus, the warrant's value depends on unpredictable events like asset liquidation or legal resolutions. Investors should be aware that this investment carries an extremely high risk of complete loss. Any value in the warrants is purely based on the potential for recovering assets or a successful legal claim by warrant holders. The future for these warrants is not bright.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Press Releases (historical)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Warrants carry significant risk of loss. This is an assessment of warrants on a company that is no longer actively trading.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apollomics Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-26 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website |
Full time employees 59 | Website | ||
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.